ArticleDermatology and therapy2026
Characteristics of Dupilumab-Treated Patients with Atopic Dermatitis Over Time: A Cross-Sectional Assessment of Potential Channeling Bias upon Pediatric Label Extension.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSelectively prescribing new medications to patients with severe disease can lead to channeling bias in observational studies. Potential for channeling upon label extension has not been described. The objective of this study was to describe dupilumab-treated patients with moderate-to-severe atopic dermatitis (AD) at initial United States Food and Drug Administration (FDA) approval for adults (March 2017) and at label extensions to adolescents (March 2019), children (May 2020), and young children (June 2022).
methodsA cross-sectional study was conducted using Optum's de-identified Clinformatics® Data Mart Database to describe baseline characteristics of patients with AD in the US who initiated dupilumab within 6 months of FDA approval or label extension.
resultsDupilumab-treated patients with AD at initial approval, versus the most recent label update, had a higher prevalence of comorbid Type 2 inflammatory diseases (e.g., asthma: 33% versus 22%), a larger proportion of prior systemic immunosuppressant use (31% versus 5%), and more frequent dermatologist visits in the previous year (mean 6.1 versus 3.1 visits). Newly licensed adolescents and children had a greater burden of atopic comorbidities and a different pattern of prior AD treatment than adults.
conclusionPatients initiating dupilumab in March 2017 had markers of high disease burden, consistent with channeling. As the label extended, the population shifted toward the indicated moderate-to-severe phenotype. Channeling trends were difficult to assess given the well-established differences in comorbidities and treatment patterns in pediatric AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.